

# Resource Summary Report

Generated by [dkNET](#) on Apr 25, 2025

## LIPID Metabolites And Pathways Strategy

RRID:SCR\_006579

Type: Tool

### Proper Citation

LIPID Metabolites And Pathways Strategy (RRID:SCR\_006579)

### Resource Information

**URL:** <http://www.lipidmaps.org/>

**Proper Citation:** LIPID Metabolites And Pathways Strategy (RRID:SCR\_006579)

**Description:** Multi-institutional supported website and database that provides access to large number of globally used lipidomics resources. Internationally led the field of lipid curation, classification, and nomenclature since 2003. Produces new open-access databases, informatics tools and lipidomics-focused training activities will be generated and made publicly available for researchers studying lipids in health and disease.

**Abbreviations:** LIPID MAPS

**Synonyms:** , LIPID Maps database, LIPID Metabolites And Pathways Strategy database, LIPID Maps

**Resource Type:** database, narrative resource, standard specification, data or information resource

**Keywords:** lipid, pathway, classification, metabolomics, metabolite, FASEB list

**Funding:** NIGMS ;  
Glue Grant

**Availability:** Free, Freely available

**Resource Name:** LIPID Metabolites And Pathways Strategy

**Resource ID:** SCR\_006579

**Alternate IDs:** nif-0000-00368, SCR\_026208

**Record Creation Time:** 20220129T080237+0000

**Record Last Update:** 20250425T055538+0000

---

## Ratings and Alerts

No rating or validation information has been found for LIPID Metabolites And Pathways Strategy.

No alerts have been found for LIPID Metabolites And Pathways Strategy.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 1099 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#).

Spangenberg P, et al. (2025) msiFlow: automated workflows for reproducible and scalable multimodal mass spectrometry imaging and microscopy data analysis. *Nature communications*, 16(1), 1065.

Tu W, et al. (2025) Investigation of the Molecular Mechanism of Asthma in Meishan Pigs Using Multi-Omics Analysis. *Animals : an open access journal from MDPI*, 15(2).

Shao Q, et al. (2025) A Single-Arm Phase II Clinical Trial of Fulvestrant Combined with Neoadjuvant Chemotherapy of ER+/HER2- Locally Advanced Breast Cancer: Integrated Analysis of 18F-FES PET-CT and Metabolites with Treatment Response. *Cancer research and treatment*, 57(1), 126.

Wang S, et al. (2025) Joint Analysis of Multiple Omics to Describe the Biological Characteristics of Resistant Hypertension. *Journal of clinical hypertension (Greenwich, Conn.)*, 27(1), e14961.

Li W, et al. (2025) Integrating proteomics and metabolomics to elucidate the regulatory mechanisms of pimpled egg production in chickens: Multi-omics analysis of the mechanism of pimpled egg formation. *Poultry science*, 104(2), 104818.

Zhao Q, et al. (2025) Dual-purpose elemental sulfur for capturing and accelerating biodegradation of petroleum hydrocarbons in anaerobic environment. *Water research X*, 26, 100290.

Wang Y, et al. (2025) Untargeted Metabolomics Reveals Key Differences Between Yak, Buffalo, and Cow Colostrum Based on UHPLC-ESI-MS/MS. *Foods (Basel, Switzerland)*, 14(2).

Li Q, et al. (2025) FBXW7 metabolic reprogramming inhibits the development of colon cancer by down-regulating the activity of arginine/mTOR pathways. *PloS one*, 20(1), e0317294.

Hou CC, et al. (2025) Specific plasma metabolite profile in intestinal Behçet's syndrome. *Orphanet journal of rare diseases*, 20(1), 21.

Luo W, et al. (2025) Perfluoropentane-based oxygen-loaded nanodroplets reduce microglial activation through metabolic reprogramming. *Neural regeneration research*, 20(4), 1178.

Chamoso-Sanchez D, et al. (2025) Unveiling cellular changes in leukaemia cell lines after cannabidiol treatment through lipidomics. *Scientific reports*, 15(1), 2238.

Li X, et al. (2024) Gut microbes combined with metabolomics reveal the protective effects of Qijia Rougan decoction against CCl<sub>4</sub>-induced hepatic fibrosis. *Frontiers in pharmacology*, 15, 1347120.

Vicari M, et al. (2024) Spatial multimodal analysis of transcriptomes and metabolomes in tissues. *Nature biotechnology*, 42(7), 1046.

Yang F, et al. (2024) Characterization of lipid composition and nutritional quality of yak ghee at different altitudes: A quantitative lipidomic analysis. *Food chemistry: X*, 21, 101166.

Zhang Z, et al. (2024) Integrated omics analysis reveals the alteration of gut microbiota and fecal metabolites in *Cervus elaphus kansuensis*. *Applied microbiology and biotechnology*, 108(1), 125.

Sergeant K, et al. (2024) Exploration of the Diversity of Vicine and Convicine Derivatives in Faba Bean (*Vicia faba* L.) Cultivars: Insights from LC-MS/MS Spectra. *Molecules (Basel, Switzerland)*, 29(5).

Guo J, et al. (2024) Inhibition of the NF- $\kappa$ B/HIF-1 $\alpha$  signaling pathway in colorectal cancer by tyrosol: a gut microbiota-derived metabolite. *Journal for immunotherapy of cancer*, 12(9).

Wang R, et al. (2024) Selectively targeting the AdipoR2-CaM-CaMKII-NOS3 axis by SCM-198 as a rapid-acting therapy for advanced acute liver failure. *Nature communications*, 15(1), 10690.

Yu H, et al. (2024) Effects of seasonal climates and MIPS1 mutations on soybean germination through multi-omics analysis. *BMC plant biology*, 24(1), 1231.

Hu Y, et al. (2024) Microbiome and metabolomics reveal the effect of gut microbiota on liver regeneration of fatty liver disease. *EBioMedicine*, 111, 105482.